Amylyx Pharmaceuticals, Inc. AMLX
Amylyx Pharmaceuticals, Inc. (also referred to as Amylyx, we, our or us) is a clinical-stage pharmaceutical company with a mission to develop and advance novel therapies for communities with high unmet medical needs. We have preclinical and clinical development programs underway in endocrine conditions and neurodegenerative diseases. We are advancing a pipeline in which we have matched investigational therapies with diseases for which we believe these therapies can make the greatest impact, based on well-defined mechanistic rationales, clear clinical outcomes and biomarkers, and rigorous preclinical data, agnostic of modality. Our current pipeline is represented in the table below.
Our lead investigational asset is avexitide, a first-in-class glucagon-like peptide-1, or GLP-1, receptor antagonist. Avexitide has been evaluated as a treatment for PBH and congenital hyperinsulinism, or Congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. The U.S. Food and Drug Administration, or the FDA, has granted avexitide Breakthrough Therapy Designation for both PBH and HI, Rare Pediatric Disease Designation in Congenital HI, and Orphan Drug Designation for the treatment of hyperinsulinemic hypoglycemia.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $87.4M | $380.8M | $22.2M | $285.0K | — |
| Cost of revenue | $0 | $6.0M | $25.4M | $3.0M | — | — |
| Gross profit | $0 | $81.4M | $355.3M | $19.2M | — | — |
| R&D | $90.4M | $104.1M | $128.2M | $93.5M | $44.0M | — |
| SG&A | $62.9M | $114.3M | $188.4M | $127.1M | $38.9M | — |
| Total operating expenses | $153.3M | $402.1M | $342.0M | $223.6M | $83.0M | — |
| Operating income | -$153.3M | -$314.7M | $38.8M | -$201.3M | -$82.7M | — |
| Pre-tax income | -$144.7M | -$302.1M | $54.3M | -$197.6M | -$87.9M | — |
| Income tax | $46.0K | $393.0K | $5.0M | $774.0K | — | — |
| Net income | -$144.7M | -$301.7M | $49.3M | -$198.4M | -$87.9M | — |
| EPS, basic | -1.53 | -4.43 | 0.73 | -3.39 | -13.35 | — |
| EPS, diluted | -1.53 | -4.43 | 0.70 | -3.39 | -13.35 | — |
| Shares, diluted (wtd. avg.) | 94.6M | 68.1M | 70.0M | 58.5M | 6.6M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $226.7M | $77.4M | $170.2M | $62.5M | $50.2M | — |
| Short-term investments | $90.3M | $99.1M | $201.2M | $284.4M | $45.9M | — |
| Receivables | $88.0K | $447.0K | $40.0M | $15.3M | — | — |
| Inventory | — | — | $38.3M | $9.8M | — | — |
| Total current assets | $323.7M | $189.4M | $464.7M | $382.1M | $105.0M | — |
| Property, plant and equipment | $310.0K | $961.0K | $2.7M | $2.6M | $474.0K | — |
| Total assets | $332.6M | $193.6M | $517.5M | $391.5M | $105.6M | — |
| Accounts payable | $3.5M | $2.9M | $22.1M | $6.3M | $4.4M | — |
| Total current liabilities | $22.7M | $28.4M | $82.0M | $46.6M | $17.4M | — |
| Total liabilities | $27.4M | $28.9M | $84.0M | $50.8M | $17.4M | — |
| Retained earnings | -$751.4M | -$606.7M | -$304.9M | -$354.2M | -$155.8M | — |
| Total equity | $305.3M | $164.8M | $433.4M | $340.6M | -$151.2M | -$66.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$123.3M | -$167.6M | $11.9M | -$179.9M | -$74.8M | — |
| Depreciation and amortisation | $525.0K | $904.0K | $1.1M | $487.0K | $52.0K | — |
| Stock-based compensation | $27.6M | $33.0M | $37.2M | $21.7M | $3.1M | — |
| Capital expenditure | $138.0K | $157.0K | $1.2M | $2.5M | $353.0K | — |
| Investing cash flow | $14.0M | $75.7M | $92.1M | -$239.0M | -$46.4M | — |
| Financing cash flow | $257.0M | $348.0K | $3.5M | $431.8M | $158.5M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-171800.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $285.0K | $22.2M | $380.8M | $87.4M | $0 |
| Gross profit | — | — | $19.2M | $355.3M | $81.4M | $0 |
| Net income | — | -$87.9M | -$198.4M | $49.3M | -$301.7M | -$144.7M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |